Journey Medical (DERM) Net Income towards Common Stockholders (2020 - 2026)

Journey Medical (DERM) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$2.2 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 45.25% year-over-year to -$2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.6 million (down 16.11% YoY) and the FY2025 annual result came in at -$11.4 million, up 22.21% from the prior year.
• Net Income towards Common Stockholders retreated to -$2.2 million in Q1 2026, from -$1.2 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $16.8 million in Q3 2023 to a low of -$10.6 million in Q4 2022.
• A 5-year average of -$3.6 million and a median of -$3.4 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• The widest YoY moves for Net Income towards Common Stockholders: up 266.56% in 2023, down 635.56% in 2023.
• Tracing DERM's Net Income towards Common Stockholders over 5 years: stood at -$10.6 million in 2022, then jumped by 79.86% to -$2.1 million in 2023, then jumped by 173.82% to $1.6 million in 2024, then slumped by 177.69% to -$1.2 million in 2025, then slumped by 81.45% to -$2.2 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$2.2 million (Q1 2026), -$1.2 million (Q4 2025), and -$2.3 million (Q3 2025), per Business Quant data.